In this context, results from ongoing clinical trials, aimed at understanding whether repressing RAGE axis is beneficial at relieving both Ins resistance and BC progression, may contribute to build up critical knowledge that will turn useful in translational purposes [ClinicalTrials.gov identifier: NCT03092635]. Here, AGER is linked to breast cancer.